The 2019 Genitourinary Pathology Society (GUPS) White Paper on Contemporary Grading of Prostate Cancer.

Epstein, Jonathan I; Amin, Mahul B; Fine, Samson W; Algaba, Ferran; Aron, Manju; Baydar, Dilek E; Beltran, Antonio Lopez; Brimo, Fadi; Cheville, John C; Colecchia, Maurizio; Comperat, Eva; da Cunha, Isabela Werneck; Delprado, Warick; DeMarzo, Angelo M; Giannico, Giovanna A; Gordetsky, Jennifer B; Guo, Charles C; Hansel, Donna E; Hirsch, Michelle S; Huang, Jiaoti; ... (2021). The 2019 Genitourinary Pathology Society (GUPS) White Paper on Contemporary Grading of Prostate Cancer. Archives of pathology & laboratory medicine, 145(4), pp. 461-493. College of American Pathologists 10.5858/arpa.2020-0015-RA

[img] Text
10.5858_arpa.2020-0015-ra.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (8MB) | Request a copy

CONTEXT.—

Controversies and uncertainty persist in prostate cancer grading.

OBJECTIVE.—

To update grading recommendations.

DATA SOURCES.—

Critical review of the literature along with pathology and clinician surveys.

CONCLUSIONS.—

Percent Gleason pattern 4 (%GP4) is as follows: (1) report %GP4 in needle biopsy with Grade Groups (GrGp) 2 and 3, and in needle biopsy on other parts (jars) of lower grade in cases with at least 1 part showing Gleason score (GS) 4 + 4 = 8; and (2) report %GP4: less than 5% or less than 10% and 10% increments thereafter. Tertiary grade patterns are as follows: (1) replace "tertiary grade pattern" in radical prostatectomy (RP) with "minor tertiary pattern 5 (TP5)," and only use in RP with GrGp 2 or 3 with less than 5% Gleason pattern 5; and (2) minor TP5 is noted along with the GS, with the GrGp based on the GS. Global score and magnetic resonance imaging (MRI)-targeted biopsies are as follows: (1) when multiple undesignated cores are taken from a single MRI-targeted lesion, an overall grade for that lesion is given as if all the involved cores were one long core; and (2) if providing a global score, when different scores are found in the standard and the MRI-targeted biopsy, give a single global score (factoring both the systematic standard and the MRI-targeted positive cores). Grade Groups are as follows: (1) Grade Groups (GrGp) is the terminology adopted by major world organizations; and (2) retain GS 3 + 5 = 8 in GrGp 4. Cribriform carcinoma is as follows: (1) report the presence or absence of cribriform glands in biopsy and RP with Gleason pattern 4 carcinoma. Intraductal carcinoma (IDC-P) is as follows: (1) report IDC-P in biopsy and RP; (2) use criteria based on dense cribriform glands (>50% of the gland is composed of epithelium relative to luminal spaces) and/or solid nests and/or marked pleomorphism/necrosis; (3) it is not necessary to perform basal cell immunostains on biopsy and RP to identify IDC-P if the results would not change the overall (highest) GS/GrGp part per case; (4) do not include IDC-P in determining the final GS/GrGp on biopsy and/or RP; and (5) "atypical intraductal proliferation (AIP)" is preferred for an intraductal proliferation of prostatic secretory cells which shows a greater degree of architectural complexity and/or cytological atypia than typical high-grade prostatic intraepithelial neoplasia, yet falling short of the strict diagnostic threshold for IDC-P. Molecular testing is as follows: (1) Ki67 is not ready for routine clinical use; (2) additional studies of active surveillance cohorts are needed to establish the utility of PTEN in this setting; and (3) dedicated studies of RNA-based assays in active surveillance populations are needed to substantiate the utility of these expensive tests in this setting. Artificial intelligence and novel grading schema are as follows: (1) incorporating reactive stromal grade, percent GP4, minor tertiary GP5, and cribriform/intraductal carcinoma are not ready for adoption in current practice.

Item Type:

Journal Article (Review Article)

Division/Institute:

04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Präzisionsonkologie
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Präzisionsonkologie

04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR)

UniBE Contributor:

Rubin, Mark Andrew

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0003-9985

Publisher:

College of American Pathologists

Language:

English

Submitter:

Marla Rittiner

Date Deposited:

29 Dec 2020 10:25

Last Modified:

26 Mar 2021 01:33

Publisher DOI:

10.5858/arpa.2020-0015-RA

PubMed ID:

32589068

BORIS DOI:

10.48350/150184

URI:

https://boris.unibe.ch/id/eprint/150184

Actions (login required)

Edit item Edit item
Provide Feedback